Clovis Oncology, Inc. (Nasdaq: CLVS) announced today the pricing of its underwritten public offering of 3,750,000 shares of its common stock at $20.00 per share, before underwriting discounts and commissions. In addition, the underwriters have a 30-day option to purchase up to an additional 562,500 shares of common stock from Clovis Oncology to cover over-allotments, if any.
The offering is expected to close on April 10, 2012, subject to customary closing conditions.
J. P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering, and Leerink Swann LLC is acting as co-manager for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 3, 2012. This offering is being made only by means of a prospectus, copies of which may be obtained from J. P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204 or from Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010 or by calling toll-free (800) 221-1037 or emailing a request to
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops diagnostic tools that direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in San Francisco, California and Cambridge, UK.